Literature DB >> 17430152

Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development.

Keith Q Tanis1, Samuel S Newton, Ronald S Duman.   

Abstract

Preclinical and clinical studies have demonstrated that stress and depression result in cell atrophy and loss in limbic and cortical brain regions while antidepressants reverse these effects. In concert with these findings, reduced expression of numerous genes that mediate neurotrophin and growth factor signaling has been observed in depressed patients and in stressed animals. Further, antidepressants are known to elevate the expression of multiple genes involved in these signaling pathways. Together, these findings have implicated neurotrophic factors in both the etiology and treatment of depression. Below we review the current data supporting the neurotrophic hypothesis of depression, and discuss potential approaches to pharmacologically upregulate neurotrophic/growth factor signaling to elicit antidepressant responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430152     DOI: 10.2174/187152707780363276

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  18 in total

Review 1.  Evidence demonstrating role of microRNAs in the etiopathology of major depression.

Authors:  Yogesh Dwivedi
Journal:  J Chem Neuroanat       Date:  2011-04-14       Impact factor: 3.052

2.  Depressive symptoms, antidepressant use, and brain volumes on MRI in a population-based cohort of old persons without dementia.

Authors:  Mirjam I Geerlings; Adam M Brickman; Nicole Schupf; Davangere P Devanand; José A Luchsinger; Richard Mayeux; Scott A Small
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

Review 4.  From synapse to nucleus: novel targets for treating depression.

Authors:  Herbert E Covington; Vincent Vialou; Eric J Nestler
Journal:  Neuropharmacology       Date:  2009-12-17       Impact factor: 5.250

5.  Effects of the anti-multiple sclerosis immunomodulator laquinimod on anxiety and depression in rodent behavioral models.

Authors:  Irit Gil-Ad; Ben H Amit; Liat Hayardeni; Igor Tarasenko; Michal Taler; Ravit Uzan Gueta; Abraham Weizman
Journal:  J Mol Neurosci       Date:  2014-07-27       Impact factor: 3.444

Review 6.  Dynamic nature of the p75 neurotrophin receptor in response to injury and disease.

Authors:  Rick Meeker; Kimberly Williams
Journal:  J Neuroimmune Pharmacol       Date:  2014-09-20       Impact factor: 4.147

Review 7.  The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.

Authors:  Gabriele Masi; Paola Brovedani
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

8.  The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus.

Authors:  Smita Thakker-Varia; Jennifer Jernstedt Krol; Jacob Nettleton; Parizad M Bilimoria; Debra A Bangasser; Tracey J Shors; Ira B Black; Janet Alder
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

9.  The (Eigen)value of diffusion tensor imaging to investigate depression after traumatic brain injury.

Authors:  Jerome J Maller; Richard H S Thomson; Kerstin Pannek; Stephen E Rose; Neil Bailey; Philip M Lewis; Paul B Fitzgerald
Journal:  Hum Brain Mapp       Date:  2012-09-24       Impact factor: 5.038

10.  Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.

Authors:  Srijan Sen; Ronald Duman; Gerard Sanacora
Journal:  Biol Psychiatry       Date:  2008-06-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.